BioCentury
ARTICLE | Clinical News

AKB-9778: Phase IIa data

July 20, 2015 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients showed that twice-daily 15 mg subcutaneous AKB-9778 plus once-monthly Lucentis ranibizumab significantly reduced CST f...